RTX 001 - Resolution Therapeutics
Alternative Names: RTX-001 - Resolution TherapeuticsLatest Information Update: 02 Dec 2024
At a glance
- Originator Resolution Therapeutics
- Class Anti-inflammatories; Antifibrotics; Cell therapies; Gene therapies
- Mechanism of Action Macrophage replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Liver cirrhosis
Most Recent Events
- 19 Nov 2024 Resolution Therapeutics plans the phase I/II EMERALD trial for Liver cirrhosis in Spain (IV) in the second quarter of 2025
- 19 Nov 2024 Spanish Agency of Medicines and Medical Products approves Clinical Trial application for RTX 001 to initiate the phase I/II EMERALD trial in Liver cirrhosis
- 15 Nov 2024 Pharmacodynamics data from preclinical studies in Liver diseases presented at the 75th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2024)